Nebenwirkungen · Lunsumio
Lunsumio 1 mg concentrate for solution for infusion Lunsumio 30 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-148514 · Präparat HOS-099926
Summary of safety profile The adverse reactions described in this section were identified from the pivotal clinical trial GO29781 in patients treated at the recommended intravenous dose (n=218) and the recommended subcutaneous dose (n=139). Patients had follicular lymphoma (51.8%), diffuse large B-cell lymphoma (26.9%), transformed follicular lymphoma (9.8%) mantle cell lymphoma (7.3%), Richter’s transformation (3.9%), and other histologies (0.3%). The median number of cycles of Lunsumio intravenously received was 8 (range 1 -17), 37% of patients received 8 cycles, and 15% received more than 8 cycles up to 17 cycles.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-07T15:05:00Z · SHA-256 a2ee59741e6f5b14dd4aa21cd069422f86ba73f8dcfa924635f33b255e1e3671 · Passage 9d0ab8ac37fd3c152bf0c4484d0325d37d4630cc5454a2c856e6de8ed2826be1 · Zeichen 0–624 im Abschnitt